» Articles » PMID: 24252907

HE4 Transcription- and Splice Variants-specific Expression in Endometrial Cancer and Correlation with Patient Survival

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2013 Nov 21
PMID 24252907
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the HE4 variant-specific expression patterns in various normal tissues as well as in normal and malignant endometrial tissues. The relationships between mRNA variants and age, body weight, or survival are analyzed. ICAT-labeled normal and endometrial cancer (EC) tissues were analyzed with multidimensional liquid chromatography followed by tandem mass spectrometry. Levels of HE4 mRNA variants were measured by real-time PCR. Mean mRNA levels were compared among 16 normal endometrial samples, 14 grade 1 and 14 grade 3 endometrioid EC, 15 papillary serous EC, and 14 normal human tissue samples. The relationship between levels of HE4 variants and EC patient characteristics was analyzed with the use of Pearson correlation test. We found that, although all five HE4 mRNA variants are detectable in normal tissue samples, their expression is highly tissue-specific, with epididymis, trachea, breast and endometrium containing the highest levels. HE4-V0, -V1, and -V3 are the most abundant variants in both normal and malignant tissues. All variants are significantly increased in both endometrioid and papillary serous EC, with higher levels observed in grade 3 endometrioid EC. In the EC group, HE4-V1, -V3, and -V4 levels inversely correlate with EC patient survival, whereas HE4-V0 levels positively correlate with age. HE4 variants exhibit tissue-specific expression, suggesting that each variant may exert distinct functions in normal and malignant cells. HE4 levels appear to correlate with EC patient survival in a variant-specific manner. When using HE4 as a biomarker for EC management, the effects of age should be considered.

Citing Articles

Detection of serum HE4 levels contributes to the diagnosis of lung cancer.

Li J, Li Y, Huo L, Sun R, Liu X, Gu Q Oncol Lett. 2023; 25(6):255.

PMID: 37205918 PMC: 10189848. DOI: 10.3892/ol.2023.13841.


Photothermal enhanced fluorescence quenching of Tb-norfloxacin for ultrasensitive human epididymal 4 detection.

Du L, Chen Y, Huang Y, Yan S, Zhang S, Dai H Mikrochim Acta. 2023; 190(3):108.

PMID: 36867247 DOI: 10.1007/s00604-023-05689-z.


HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial Cancer: A Review.

Mais V, Fais M, Peiretti M, Fanni D, Massa E, Carboni G Curr Oncol. 2022; 29(11):8540-8555.

PMID: 36354733 PMC: 9689414. DOI: 10.3390/curroncol29110673.


Molecular Biomarkers for the Early Detection of Ovarian Cancer.

Zhang R, Siu M, Ngan H, Chan K Int J Mol Sci. 2022; 23(19).

PMID: 36233339 PMC: 9569881. DOI: 10.3390/ijms231912041.


Roles of Antimicrobial Peptides in Gynecological Cancers.

Zhao C, Yan S, Song Y, Xia X Int J Mol Sci. 2022; 23(17).

PMID: 36077500 PMC: 9456504. DOI: 10.3390/ijms231710104.


References
1.
Kirchhoff C . Molecular characterization of epididymal proteins. Rev Reprod. 1998; 3(2):86-95. DOI: 10.1530/ror.0.0030086. View

2.
Scholler N, Lowe K, Bergan L, Kampani A, Ng V, Forrest R . Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res. 2008; 14(9):2647-55. PMC: 2744596. DOI: 10.1158/1078-0432.CCR-07-1442. View

3.
Yildiz A, Yetimalar H, Kasap B, Aydin C, Tatar S, Soylu F . Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2012; 164(2):191-5. DOI: 10.1016/j.ejogrb.2012.05.038. View

4.
Sebastianelli A, Renaud M, Gregoire J, Roy M, Plante M . Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease. J Obstet Gynaecol Can. 2010; 32(9):856-860. DOI: 10.1016/S1701-2163(16)34657-6. View

5.
Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H . Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A. 2003; 100(10):5778-82. PMC: 156277. DOI: 10.1073/pnas.1037154100. View